Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jul 23, 2026
Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript
01:18pm, Wednesday, 07'th May 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
10:35am, Wednesday, 07'th May 2025
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
09:10am, Wednesday, 07'th May 2025
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
07:00am, Wednesday, 07'th May 2025
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2025 financial results and business highlights.
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
07:00am, Tuesday, 06'th May 2025
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in the following May investor conferences: BofA Securit
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
07:00am, Wednesday, 30'th Apr 2025
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:06am, Tuesday, 29'th Apr 2025
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Announces Craig Wheeler to Join the Board of Directors
07:00am, Monday, 21'st Apr 2025
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors,
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
10:15am, Wednesday, 02'nd Apr 2025
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
02:11pm, Tuesday, 01'st Apr 2025
The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (p
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FD
Apellis Pharmaceuticals: A Mixed Bag
02:06pm, Wednesday, 05'th Mar 2025
Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complica
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
02:04pm, Wednesday, 05'th Mar 2025
Last week, Apellis Pharmaceuticals Inc APLS reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
12:01pm, Monday, 03'rd Mar 2025
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript
02:08am, Sunday, 02'nd Mar 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Cedric Francois - Co-Founder and CEO Caroline Baumal - Chief Medical Off
